BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- Conditions
- Metastatic Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: Subcutaneous TislelizumabDrug: Intravenous Tislelizumab
- First Posted Date
- 2025-06-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 351
- Registration Number
- NCT07043400
- Locations
- 🇺🇸
Ironwood Cancer and Research Centers, Chandler, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Cancer and Blood Specialty Clinic, Los Alamitos, California, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-06-05
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 27
- Registration Number
- NCT07005713
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-05-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 500
- Registration Number
- NCT06973187
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-05-14
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 150
- Registration Number
- NCT06970743
- Locations
- 🇨🇳
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Peking University Peoples Hospital, Beijing, Beijing, China
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 630
- Registration Number
- NCT06943872
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Scripps Prebys Cancer Center, San Diego, California, United States
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2025-04-02
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 30
- Registration Number
- NCT06906809
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc, Madison, Wisconsin, United States
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- Conditions
- CLLChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 250
- Registration Number
- NCT06846671
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
🇺🇸Oncology Associates of Oregon Willamette Valley Cancer Center, Eugene, Oregon, United States
🇮🇹Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico, Milano, Italy
A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2025-01-31
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 80
- Registration Number
- NCT06803680
- Locations
- 🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States
🇺🇸Adventhealth, Celebration, Florida, United States
🇺🇸Florida Cancer Specialists and Research Institute, Lake Mary, Florida, United States
A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants
- First Posted Date
- 2025-01-15
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 8
- Registration Number
- NCT06776679
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Inc, Madison, Wisconsin, United States
A Study of Different Forms of BGB-43395 and Food Effect in Healthy Participants
- First Posted Date
- 2025-01-07
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 48
- Registration Number
- NCT06761898
- Locations
- 🇺🇸
Fortrea Cru, Daytone Beach, Daytona Beach, Florida, United States